There are few vaccination strategies available for the reproducible generation of a cytotoxic T cell (CTL) response, particularly in the setting of immunizing against a tumor antigen. Plasmid-based DNA vaccination offers several advantages as compared to MHC class I peptide-based vaccines or DNA immunization using viral vectors. Plasmid-based DNA vaccines are easily produced, can potentially elicit both an MHC class I and class II response, and have little infectious potential. Plasmid-based vaccines, however, have been poorly immunogenic. The systemic immune response generated after plasmid vaccination relies on in vivo transfection of local antigen presenting cells (APC) and both direct presentation and ™cross priming∫ of antigen by professional and non-professional APC. Therefore, methods to enhance the function of APC, such as simultaneous inoculation with plasmids encoding cytokine genes, has resulted in an enhancement of detectable immunity after vaccination. We questioned whether local application of soluble cytokines would be effective in enhancing the systemic immune response elicited after DNA vaccination. Using a self-tumor antigen model, we vaccinated rats with a plasmid-based rat neu intracellular domain (ICD) DNA construct and either no adjuvant, soluble GM-CSF, or IL-12. We demonstrate that the addition of soluble GM-CSF or IL-12 to rat neu ICD DNA vaccination elicits detectable neu specific T cell immunity; specifically the generation of CTL. Antibodies directed against rat neu were not elicited with this approach, indicating that the neu specific T cell immune response elicited with plasmid DNA was skewed towards cell-mediated rather than humoral immunity.
Introduction
Induction of a cytolytic T lymphocyte (CTL) response requires tumor epitopes be presented via major histocompatibility (MHC) class I molecules indicating intracellular expression of tumor proteins. A common clinical method for generating tumor antigen specific CTL is to bypass the require-ment for intracellular processing of protein and immunize subjects with peptides designed to bind exogenously to MHC class I. Peptide-based immunization, however, has been problematic with the generation of peptide-restricted T cells that do not respond to endogenous levels of peptide presented in the MHC of tumor cells (Zaks & Rosenberg, 1998) , the generation of short-lived low level immunity (Knutson et al., 2002) , and the necessity of knowing the specific peptide motifs appropriate for the variety of different MHC class I molecules. An alternative method of immunization, designed to allow expression of tumor antigen proteins within the cell, is to vaccinate patients with viral vectors encoding the antigen. Endogenous expression of tumor antigen within an antigen presenting cell (APC) would result in generating T cells capable of responding to naturally processed levels of peptides, would avoid MHC restriction issues, and would allow T cell help to be stimulated via presentation of epitopes within MHC class II. However, viral based methods of immunization have been limited by the potent immunogenicity of the viral carrier making multiple immunizations problematic and posing a theoretical potential for infection in immune-compromised cancer patients. Plasmid DNA vaccines have been shown to elicit potent cell-mediated immune responses, notably with production of antigen-specific CTL and a Th1-biased phenotype of cytokine secretion Raz et al., 1996; Donnelly et al., 1997; Iwasaki et al., 1997) . As CTL are believed to be critical in effective antitumor immunity (Markiewicz & Gajewski, 1999) , DNA-based immunization strategies are of particular interest in the development of tumor vaccines (Irvine & Restifo, 1995) .
Unfortunately, the clinical translation of plasmid DNA immunization has been considerably difficult. Some studies have suggested that the immune response elicited by DNA vaccines to foreign antigens is lower in magnitude compared with proteinbased vaccines and requires multiple booster immunizations (Raz et al., 1996) . The low immunogenicity of DNA vaccines is a major problem when contemplating the development of cancer vaccines as the immunizing antigens are often self proteins and tolerance is a mechanism of tumor escape from immune surveillance (Nanda & Sercarz, 1995) . Immune responses initiated after plasmid-based DNA vaccination are thought to be mediated by either direct transfection of APC in vivo or uptake of antigen via ™cross presentation∫ by phagocytosis of non-APC transfected cells (Shedlock & Weiner, 2000) . Therefore, APC, such as Langerhans cells (LC), play a major role in stimulating a systemic antigen-specific immune response after plasmidbased immunization. To that end, many groups have investigated the use of plasmid vectors encoding cytokine genes that may effect the immune microenvironment and enhance the function of local APC. The use of vectors encoding cytokine genes raises the concern of the effect of potential long-term cytokine production in vivo.
Local APC recruitment, maturation, and migration can be influenced by the application of soluble cytokines to the area of immunization. We have previously reported the efficacy and safety of soluble GM-CSF used as a vaccine adjuvant with peptide based vaccines both in an animal model (Disis et al., 1996) and in a human clinical trial (Knutson et al., 2001) . Since plasmid vectors encoding GM-CSF and IL-12 have been shown to enhance immune responses when co-immunized with a plasmid DNA vaccine (Xiang & Ertl, 1995; Kim et al., 1997a) , we questioned whether soluble cytokines could function as a vaccine adjuvant in DNA vaccines without being encoded into the plasmid. The use of soluble cytokines may circumvent the safety concerns associated with a plasmid encoding a cytokine in human clinical trials. We used a self-tumor antigen model, immunizing rats with plasmid encoding rat neu intracellular domain (ICD) and either soluble GM-CSF, or IL-12 as an adjuvant. Data presented here demonstrates vaccination with rat neu plasmid DNA and soluble GM-CSF or IL-12 given intradermally (id.) into the LC compartment, results in the generation of detectable systemic levels of neuspecific T cell immunity.
Materials and Methods

Animals
Rats used in this study were Fischer strain 344 (CDF (F-344)/CrlBR) (Charles River Laboratories, Portage MI). Animals were maintained at the University of Washington animal facilities under specific pathogen-free conditions and routinely used for experimental studies between 3 and 4 months of age.
Reagents
DNA immunization was performed with rat neu ICD inserted in pVR1012 (p-rICD), a eukaryotic expression vector (Vical, San Diego, CA). The plasmid uses kanamycin resistance for selection in E. coli. Plasmid DNA was purified using a Qiagen column (Valencia, CA) and was documented as endotoxin free. Recombinant rat ICD protein was kindly provided by Dr. Paul Sleath (Corixa Corp., Seattle, WA). MATB, a Fischer rat mammary adenocarcinoma (ATCC CRL-1666) were used as a target in chromium release assays (American Type Culture Collection, Rockville, MD). K562 cells (ATCC CCL-243), used in cold target inhibition, were also obtained from ATCC.
Immunizations
Those animals who received plasmid-based vaccinations were immunized id. with 100 mg of p-rICD in PBS, with 5 mg of murine GM-CSF (Immunex Corp., Seattle, WA), or with 40 ng of murine IL-12 (R & D Systems, Minneapolis, MN). In addition, a group of control animals immunized id. with each adjuvant alone without p-rICD, GM-CSF (5 mg) and IL-12 (40 ng), were evaluated. In all groups, animals underwent 2 immunizations each 14 ± 16 days apart. Eighteen to twenty days after the second immunization animals were assessed for immunologic response. Sera and spleens were harvested from immunized animals. Experiments included 5-animals/experimental group. Data shown here were derived from two separate immunization experiments for each group performed 2 months apart.
Evaluation of neu-specific proliferative T cell response
For analysis of neu protein-specific responses, immune spleen cells were harvested by mechanical disruption and passage through wire mesh and washed. Spleen cells (2 Â 10 5 /well) were plated into 96-well round bottom microtiter plates (Corning, Coring, NY) with 6 replicates per experimental group. The media used was EHAA 120 (Biofluids, Rockville, MD) with L-glutamine, penicillin/streptomycin, 2-mercaptoethanol, and 5% FBS. Cells were incubated with 0 ± 2.0 mg/ml of recombinant rat neu ICD or ovalbumin as a negative control protein. After 4 days, wells were pulsed with 1 mCi of [ 3 H] thymidine for 6 ± 8 hours and counted. Data is expressed as the mean and standard deviation cpm for each experimental group.
Evaluation of a neu-specific cytotoxic T cell response MATB targets were prepared by infection with either wild type vaccinia virus (wtv, control) or a modified vaccinia construct containing the human ICD (vhICD) . Previous studies have shown that the vaccinated rat neu ICD response is cross reactive with human ICD (Disis et al., 1998) . Five million MATB cells were incubated in media with the appropriate vaccinia construct at 5 Â 10 6 pfu/million MATB cells along with 51 Cr overnight. A multiplicity of infection of 5 : 1 was sufficient to infect target cells and consistent expression of human ICD protein was observed in MATB after infection as determined by Western blot analysis of cell lysates (data not shown). After incubation, the labeled and infected cells were harvested and washed twice in media. Spleen cells derived from the experimental groups were incubated with the appropriate targets at a 10 : 1, 20 : 1, and 40 : 1 effector-to-target (E : T) ratio in quadruplicate in 96-well V-bottom plates (Corning). After 4 hours of co-incubation at 37 8C, the plates were centrifuged and 50 ml of medium from each well was assayed for 51 Cr content. In some experiments, K562 cells were added as cold target inhibitors at the same ratio as the MATB B targets. The % specific lysis (sample well release-basal release)/(release due to mechanical disruption-basal release). Data is expressed as the mean and standard deviation for each experimental group.
Evaluation of neu-specific antibody response
Serologic evaluation of rat neu specific antibody immunity was performed as previously described (Disis et al., 1998) . The optical density (OD) was read at 450 nm. The OD of each serum dilution was calculated as the OD of the rat neu coated wells minus the OD of the BSA coated wells. Positive control sera was derived from previous experiments where rats were immunized with human ICD protein in complete Freud's adjuvant (Disis et al., 1998) .
Statistical analysis
One-sided, unpaired t tests were performed using GraphPad InStat version 3.05 for Windows 95/NT (GraphPad Software, San Diego California). p values were considered significant when < 0.05.
Results
Rat neu-specific T cell immunity could be elicited after neu DNA immunization with either GM-CSF or IL-12 as soluble adjuvants An antigen-specific blastogenic response was assessed using thymidine incorporation assays. Animals immunized with the p-rICD without adjuvant (i.e. PBS alone) did not develop a detectable rat neu ICD-specific T cell response (Fig. 1A) . At the most concentrated dose of antigen, 2.0 mg ICD protein, the mean cpm was 1136 AE 177 and this value did not differ significantly from the ovalbumin control response at 2.0 mg protein, 1118 AE 200 (p 0.42). The mean cpm of unstimulated lymphocytes in this group was 1 529 AE 111. Fig. 1B demonstrates rat ICD immunity developed when soluble GM-CSF was used as a vaccine adjuvant. Animals immunized with p-rICD and GM-CSF developed a T cell proliferative response to rat neu ICD protein at the highest concentration tested, cpm 6 010 AE 101 as compared to ovalbumin 3 099 AE 98 (p < 0.01). Animals immunized with GM-CSF alone had a mean cpm to rat neu ICD of 2 872 AE 257. The mean cpm of unstimulated lymphocytes in this group was 2 322 AE 215. Finally, responses elicited with IL-12 as a soluble adjuvant were also significant (Fig. 1C) . Animals immunized with p-rICD and IL-12 developed a proliferative response to rat neu ICD, as example, at the highest protein concentration tested a cpm 7 924 AE 320 as compared to ovalbumin 3 354 AE 110 (p < 0.01). Animals immunized with IL-12 alone had a mean cpm to rat neu ICD of 1 823 AE 190. The mean cpm of unstimulated lymphocytes in this group was 2 190AE 280.
Neu-specific CTL responses could be elicited after rat neu DNA immunization and were enhanced when GM-CSF or IL-12 were used as soluble adjuvants
The generation of CTL was assessed by chromium release assays using a syngeneic tumor cell line, MATB, infected with v-hICD or wtv, as control. Rat neu ICD and human HER-2/neu ICD are highly homologous (92% at the amino acid level) and previous studies have shown that immune responses to the ICD in rat are cross-reactive between human and rat proteins (Disis et al., 1998) . Fig. 2A shows results from animals immunized with p-rICD and PBS. There was a difference in % specific lysis at the highest E : T ratio between v-hICD (8 AE 1%) infected MATB targets and those infected with wtv (4 AE 2%) (p < 0.01). Furthermore, neu specific CTL could be detected in animals immunized with p-rICD and soluble GM-CSF or IL-12 as adjuvant. Fig. 2B demonstrates a % specific lysis at the highest E : T ratio (40 : 1) of animals immunized with p-rICD and GM-CSF as a soluble adjuvant, 27 AE 4% against vhICD MATB tumor cells. Lysis was not significantly changed by adding the cold target, K562 (28 AE 7%).
Tumor cells infected with wtv demonstrated lysis at 40 : 1 of 8 AE 4% (p < 0.01). Animals immunized with cytokine alone did not lyse ICD expressing targets, (4 AE 3%). Similarly, animals immunized with p-rICD and soluble IL-12 developed neuspecific CTL. Fig. 2C demonstrates a % specific lysis at the highest E : T ratio (40 : 1) of 35 AE 4% against v-hICD expressing MATB tumor cells. Again, lysis was not significantly changed by adding the cold target, K562, (30 AE 6%). Tumor cells infected with wtv demonstrated lysis at 40 : 1 of 10 AE 3% (p < 0.01). Animals immunized with cytokine alone did not lyse ICD expressing targets, (10 AE 4%).
Antibody immunity to rat neu could not be detected after rat neu ICD DNA immunization rICD-specific antibody titers were examined using ELISA. As shown in Fig. 3 , neu plasmid DNA immunization was not effective in generating rat neuspecific antibody responses in any group tested. Also shown as a positive control is the antibody response to rICD that was generated in rats following immunization with hICD protein in CFA. Titers of 1 : 1 000 yielded an OD value of 2.4 AE 0.04 (Disis et al., 1998) . 3 . Antibody immunity to rat neu could not be detected after rat neu ICD plasmid DNA immunization. Data is shown as the mean OD and standard deviation of 10 animals in each experimental group, p-rICD in PBS (^), p-rICD with GM-CSF (*), and p-rICD with IL-12 (&). Control sera depicted with a & was derived from 5 rats immunized with purified human ICD protein (Disis et al., 1998) and had antibodies cross reactive with rat neu (mean and standard deviation).
Discussion
Vaccination with bacterial plasmid DNA encoding an immunogenic protein is being investigated as a means of antigen delivery due to many potential advantages (Donnelly et al., 1997) . First, the approach, in contrast to peptide vaccines, can be used without knowledge of the patient MHC alleles. Secondly, using DNA-encoded antigen allows accessibility to the MHC class I processing pathway, in contrast to protein-based vaccines. Furthermore, in contrast to protein or viral vector-based vaccines, DNA is relatively easy to produce, transport, is stable in long-term storage, and can withstand fluctuations in temperature. Finally, plasmid-based strategies allow the delivery of multiple antigens simultaneously. Human cancers express multiple immunogenic proteins. The generation of antigen negative variant tumors after vaccination against a single antigen is well documented and may be circumvented by multi-antigen vaccines (Jager et al., 1997; Kerkmann-Tucek et al., 1998) .
Plasmid-based DNA vaccines, however, have been only moderately successful in their translation to human clinical use. There are several reasons for the lack of success such as the low local transfection of DNA into APC as most vaccines are delivered to muscle (Gurunathan et al., 2000) . Furthermore, most APC that are transfected are ™non-professional∫ APC such as monocytes and macrophage. In addition, APC transfected in vivo by DNA, generally in muscle, do not home effectively to draining lymph nodes thus systemic immunity is not efficiently stimulated (Nakamura et al., 1999) . Our hypothesis is that plasmid DNA immunizations may be made more effective by improving the transfection of local DC in the skin, i.e. LC, using soluble cytokines as vaccine adjuvants. Data presented here demonstrates, (1) soluble cytokine adjuvants added to plasmid-based vaccines is feasible and immunogenic, i.e. can result in circumventing tolerance to neu, a ™self∫ tumor antigen, (2) T cell immunity could be augmented or enhanced with the use of soluble GM-CSF or IL-12 as an adjuvant, and, (3) plasmid-based DNA immunization was not effective in generating significant levels of neu specific antibodies suggesting a marked Th1 phenotypic response.
The use of cytokines as adjuvants in association with plasmid-based vaccines follows from the observation that DNA immunization elicits immune responses via presentation by professional APC (Iwasaki et al., 1997; Corr et al., 1999) and has led investigators to determine whether chemoattractant factors, or molecules that promote the differentiation of APC, might enhance the immune response elicited by DNA immunization. Several groups have demonstrated that co-immunization with plasmid DNA expressing immunostimulatory molecules can improve the efficacy of DNA vaccines. Xiang and Ertl (1995) reported that co-immunization of a plasmid vector encoding murine GM-CSF, but not IFN-g, enhanced T cell and B cell responses to a viral antigen in a murine system. Similar results have been shown with plasmid vectors encoding IL-2 (Chow et al., 1997) , IL-12 (Kim et al., 1997a) , the costimulatory molecules CD80 and CD86 (Kim et al., 1997b) , as well as the hematopoietic growth factor M-CSF (Kim et al., 2000) . Animal models of DNA vaccines have demonstrated that immune responses can be long-lived after vaccination (Raz et al., 1994; Davis et al., 1996) , likely due to persistent expression of the antigen in cells transfected in situ during immunization (Davis et al., 1993; Corr et al., 1996) . The persistence of plasmid DNA at the site of immunization and the demonstration that plasmid DNA can be transported to distant sites by inflammatory cells (La Cava et al., 2000) raises concerns about safety when contemplating human clinical trials and at present, the long-term implications of persistent cytokine expression are unknown. The finding that soluble cytokines may play a similar role in enhancing immune responses may allow a more rapid translation of the approach to the clinic.
Soluble GM-CSF and IL-12 were both shown to promote an antigen-specific cellular immune response, and a CTL response in particular. Previous work, by our group, in the rat, demonstrated that local id. application of GM-CSF resulted in increased influx of cells expressing high levels of MHC class II into the skin and draining lymph nodes (Disis et al., 1996) . Translation of this strategy into humans, in terms of a HER-2/neu peptide-based vaccine trial, demonstrated that local application of GM-CSF id. could result in persistent deposition of CD1a positive cells (LC) in the skin (Rinn et al., 1999) and the subsequent development of HER-2/ neu systemic T cell immunity (Knutson et al., 2001) . IL-12 is a pro-inflammatory cytokine that is secreted by activated DC and may enhance their function. Recent studies have shown that the Th1 biased responses induced by DNA vaccines are mediated by increased IL-12 production by APC (Asakura et al., 2000) . Additional IL-12 in the local environment may skew that biased response further. Furthermore, IL-12, may be critical at the initiation of an immune response to promote a Th1-type of T cell differentiation with induction of antigen-specific CTL (Nakamura et al., 1997; Fallarino & Gajewski, 1999; Murphy et al., 1999; Schmidt & Mescher, 1999) . The use of IL-12 encoded within a DNA based vaccine has resulted in strongly biased Th1 response associated with a cellular, but not a humoral response (Hanlon et al., 2001 ) and long lasting IFNg production but no production of IL-4 (Schultz et al., 2000) . The lack of detectable neu specific antibodies in animals receiving the plasmid-based vaccine indicates a strongly skewed cell-mediated immune response.
In summary, local application of soluble cytokines known to effect APC in vivo is a successful strategy in generating detectable systemic immunity to a selfantigen after plasmid DNA immunization. The observation that systemic immunity was elicited implies that APC were transduced in situ and migrated to draining lymph nodes where antigen was presented for T cell recognition. Few immunization methods are available that effectively elicit a CTL response. Plasmid-based vaccination with soluble cytokines as adjuvant may offer an immunization strategy that is able to be rapidly applied and tested in human clinical trials of cancer vaccines.
